C
Crossbow Therapeutics
TCR-mimetic antibody T-cell engagers for precision cancer immunotherapy
About Crossbow Therapeutics
Crossbow Therapeutics is a Cambridge, Massachusetts biotechnology company developing T-cell receptor mimetic (TCRm) antibody therapies — branded T-Bolt molecules — that direct T cells against cancer antigens with the goal of more precise immunotherapy and fewer off-tumor toxicities than some marketed T-cell engagers. Led by CEO Briggs Morrison, its lead program CBX-250, developed with MD Anderson Cancer Center, is in a Phase 1 CROSSCHECK-001 trial in relapsed or refractory myeloid malignancies (AML, CML, MDS and CMML), with early data expected by end of 2026; a second bispecific, CBX-663, targets a telomerase reverse transcriptase peptide present across many cancers and was advancing toward IND/Phase 1. In March 2026 Crossbow raised $77 million in Series B financing co-led by Taiho Ventures and Arkin BioCapital, with participation from MPM BioImpact, Pfizer Ventures, Polaris Partners and other investors, to advance CBX-250 through clinical development and progress CBX-663. Sources: Business Wire / BioPharma Dive 18 Mar 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Cambridge, United States
- Employees
- 46
- Open positions
- None listed
- Dealroom signal
- 83.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Mar 2026 | $77M | $308M | Polaris Partners · MPM BioImpact · BVF Partners · Eli Lilly | ↗ |
| SERIES AOther financing | Jul 2023 | $80M | $320M | Polaris Partners · Mirae Asset Venture Investment · MPM BioImpact · Mirae Asset Capital | ↗ |
Growth signals
Latest recorded traffic for Crossbow Therapeutics is 2.2K monthly website visits, down 38.9% over the last three months. Crossbow Therapeutics's team grew 12.2% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A13 investors entered at this stage
MPM BioImpact- PVPfizer Ventures
Polaris Partners
Mirae Asset Venture Investment
Mirae Asset Capital
BVF Partners
Eli Lilly- TVTaiho Ventures
Arkin Capital
Sixty Degree Capital
LifeLink Ventures- HMHamilton Square Partners Management
Leukemia & Lymphoma Society
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Crossbow Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Crossbow Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.